|

Administering Lutetium-177-PSMA-617 (PLUVICTO) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Ebrahim S Delpassand1

Indications

  • Prostate Cancer (CRPC)1
  • Prostate Cancer Patients With Bone Metastasis1
  • Metastatic Castration-resistant Prostate Cancer1
  • Prostate Cancer Metastatic1
  • Prostate Cancer1

Houston, Texas1 trial

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Excel Diagnostics & Nuclear Oncology Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.